a favorable trendp = 0.05
Data analysis for ACR70 showed a favorable trend toward anti-IL-17 (OR 2.62, 95% CI 1–6.89, p = 0.05, I2 15%).
Data analysis for ACR70 showed a favorable trend toward anti-IL-17 (OR 2.62, 95% CI 1–6.89, p = 0.05, I2 15%).
Subgroup analysis of ACR20 for individual anti-IL-17 agents showed that ixekizumab was more effective than placebo, while secukinumab showed a trend toward achieving the ACR20 response.